Lempo Therapeutics

Gene Editing for Treatment of Chronic Disease

Health Tech & Life Sciences
Active
Pre-Funding Binyamina-Giv'at Ada, Israel Founded 2017
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2017
Headcount
3
HQ
Binyamina-Giv'at Ada, Israel
Sector
Health Tech & Life Sciences

About

Lempo Therapeutics is a preclinical biotech company that uses gene editing to modify the immune system for attenuating severe chronic diseases. The companys novel, patented treatment uses an ex vivo stem cell gene-editing technique to minimize the collateral damage caused by immune system activity, thereby significantly mitigating disease progression. Lempos initial focus is on treating pulmonary arterial hypertension (PAH), a rare and devastating cardiovascular disease that leads to heart failure and death if left untreated. The companys concept has already been proven effective in animal models for the treatment of Alzheimers disease, multiple sclerosis, cardiovascular diseases, and more.

Q&A

What is Lempo Therapeutics' primary focus?
Lempo Therapeutics is a preclinical biotech company focused on using gene editing to modify the immune system for attenuating severe chronic diseases. Their initial focus is on treating pulmonary arterial hypertension (PAH).
When was Lempo Therapeutics founded?
Lempo Therapeutics was founded in December 2017.
Where is Lempo Therapeutics headquartered?
Lempo Therapeutics is headquartered in Binyamina-Giv'at Ada, Israel.
What is the current employee count for Lempo Therapeutics?
Lempo Therapeutics has 1-10 employees.
Who are the co-founders of Lempo Therapeutics?
The co-founders of Lempo Therapeutics are Oren Glanz, who serves as CEO, and Prof. Ben-Zion Garty, who leads Clinical Research.
What is Lempo Therapeutics' current funding stage?
Lempo Therapeutics is currently in the Pre-Funding stage.
Does Lempo Therapeutics hold any patents?
Yes, Lempo Therapeutics holds one patent.
What diseases has Lempo Therapeutics' concept shown effectiveness in animal models for?
Lempo Therapeutics' concept has been proven effective in animal models for the treatment of Alzheimer's disease, multiple sclerosis, and cardiovascular diseases, among others.

Team · 2

Oren Glanz
Founder · Co-founder & CEO
LinkedIn ↗
Prof. Ben-Zion Garty
Founder · Co-founder & Clinical Research

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

treatmentscardiovascularmultiple-sclerosisalzheimers-diseasechronic-diseasehospitalsbiotechnologypharmaceuticalsgene-editingimmunologystem-cellsbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)